Pre-Conditioning Methods and Novel Approaches with Mesenchymal Stem Cells Therapy in Cardiovascular Disease.
Anthony MattaVanessa NaderMarine LebrinFabian GrossAnne-Catherine PratsDaniel CussacMichel GalinierJerome RoncalliPublished in: Cells (2022)
Transplantation of mesenchymal stem cells (MSCs) in the setting of cardiovascular disease, such as heart failure, cardiomyopathy and ischemic heart disease, has been associated with good clinical outcomes in several trials. A reduction in left ventricular remodeling, myocardial fibrosis and scar size, an improvement in endothelial dysfunction and prolonged cardiomyocytes survival were reported. The regenerative capacity, in addition to the pro-angiogenic, anti-apoptotic and anti-inflammatory effects represent the main target properties of these cells. Herein, we review the different preconditioning methods of MSCs (hypoxia, chemical and pharmacological agents) and the novel approaches (genetically modified MSCs, MSC-derived exosomes and engineered cardiac patches) suggested to optimize the efficacy of MSC therapy.
Keyphrases
- mesenchymal stem cells
- left ventricular
- cardiovascular disease
- heart failure
- umbilical cord
- cell therapy
- bone marrow
- cardiac resynchronization therapy
- induced apoptosis
- hypertrophic cardiomyopathy
- type diabetes
- cell death
- left atrial
- cell cycle arrest
- anti inflammatory
- aortic stenosis
- stem cells
- endothelial cells
- atrial fibrillation
- cardiovascular events
- acute coronary syndrome
- cerebral ischemia
- brain injury
- coronary artery disease
- percutaneous coronary intervention